Drew Moghanaki: Evaluating the first 100 participants treated with lung SBRT through 2022 of the VALOR study
Drew Moghanaki shared a post on X about a recent paper by Timothy Ritter et al. published in Elsevier.
Authors: Timothy Ritter, Robert Timmerman, Hena Hanfi, Jatinder Palta, Drew Moghanaki et al.
“The VALOR study team publishes its’ observations evaluating the first 100 participants treated with lung SBRT through 2022. The planning guide is included in the appendix. Today, nearly 400 of 670 are randomized.”
Source: Drew Moghanaki/X
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.
He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023